Sensorium Therapeutics | Bonaventure Equity Portfolio Company

Bonaventure Equity Invests in Sensorium Therapeutics $30 Million Series A to Transform Mental Health Treatment with Nature-Inspired Psychoactive Medicines

Bonaventure Equity, LLC (‘BVE”), through its second fund BVE Select Fund II, L.P., a life sciences venture capital firm focused on psychedelics and cannabinoid discoveries, has invested in Sensorium Therapeutics (Sensorium) Series A Round. Sensorium, a biotechnology company leveraging medicinal chemistry, neuroscience, and machine learning to develop nature-inspired psychoactive medicines for mental health, closed a $30 million Series A financing to advance its initial asset, SENS-01, and Biodynamic Discovery PlatformTM (BDP), a drug discovery engine that rapidly identifies, synthesizes, and enhances targeted molecules as novel therapeutics. The round was led by Santé Ventures, a specialized healthcare and life sciences investment firm with participation from Route 66 Ventures, CU Healthcare Innovation Fund, and now BVE.